Navigation Links
DNA of Jesus-era shrouded man in Jerusalem reveals earliest case of leprosy
Date:12/16/2009

The DNA of a 1st century shrouded man found in a tomb on the edge of the Old City of Jerusalem has revealed the earliest proven case of leprosy. Details of the research will be published December 16 in the PloS ONE Journal.

The molecular investigation was undertaken by Prof. Mark Spigelman and Prof. Charles Greenblatt and of the Sanford F. Kuvin Center for the Study of Infectious and Tropical Diseases at the Hebrew University of Jerusalem, Prof. Carney Matheson and Ms. Kim Vernon of Lakehead University, Canada, Prof. Azriel Gorski of New Haven University and Dr. Helen Donoghue of University College London. The archaeological excavation was led by Prof. Shimon Gibson, Dr. Boaz Zissu and Prof. James Tabor on behalf of the Israel Antiquities Authority and the University of North Carolina at Charlotte.

The burial cave, which is known as the Tomb of the Shroud, is located in the lower Hinnom Valley and is part of a 1st century C.E. cemetery known as Akeldama or 'Field of Blood' (Matthew 27:3-8; Acts 1:19) - next to the area where Judas is said to have committed suicide. The tomb of the shrouded man is located next to the tomb of Annas, the high priest (6-15 C.E.), who was the father in law of Caiaphas, the high priest who betrayed Jesus to the Romans. It is thus thought that this shrouded man was either a priest or a member of the aristocracy. According to Prof. Gibson, the view from the tomb would have looked directly toward the Jewish Temple.

No second burial

What is particularly rare about this tomb is that it was clear this man, which is dated by radiocarbon methods to 1-50 C.E., did not receive a secondary burial. Secondary burials were common practice at the time, where the bones were removed after a year and placed in an ossuary (a stone bone box). In this case, however, the entrance to this part of the tomb was completely sealed with plaster. Prof. Spigelman believes this is due to the fact that this man had suffered from leprosy and died of tuberculosis, as the DNA of both diseases was found in his bones.

Historically, disfiguring diseases - particularly leprosy - caused the afflicted individuals to be ostracized from their communities. However, a number of indications the location and size of the tomb, the type of textiles used as shroud wrappings, and the clean state of the hair suggest that the shrouded individual was a fairly affluent member of society in Jerusalem and that tuberculosis and leprosy may have crossed social boundaries in the first century C.E.

Disproves Turin Shroud?

This is also the first time fragments of a burial shroud have been found from the time of Jesus in Jerusalem. The shroud is very different to that of the Turin Shroud, hitherto assumed to be the one that was used to wrap the body of Jesus. Unlike the complex weave of the Turin Shroud, this is made up of a simple two-way weave, as the textiles historian Dr. Orit Shamir was able to show.

Based on the assumption that this is representative of a typical burial shroud widely used at the time of Jesus, the researchers conclude that the Turin Shroud did not originate from Jesus-era Jerusalem.

The excavation also found a clump of the shrouded man's hair, which had been ritually cut prior to his burial. These are both unique discoveries because organic remains are hardly ever preserved in the Jerusalem area owing to high humidity levels in the ground.

Social health in antiquity

According to Prof. Spigelman and Prof. Greenblatt, the origins and development of leprosy are largely obscure. Leprosy in the Old Testament may well refer to skin rashes such as psoriasis. The leprosy known to us today was thought to have originated in India and brought over to the Near East and to Mediterranean countries in the Hellenistic period. The results from the first-century C.E. Tomb of the Shroud fill a vital gap in our knowledge of this disease.

Furthermore, the new research has shown that molecular pathology clearly adds a new dimension to the archaeological exploration of disease in ancient times and provides us with a better understanding of the evolution, geographic distribution and epidemiology of disease and social health in antiquity.

The co-infection of both leprosy and tuberculosis here and in 30 percent of DNA remains in Israel and Europe from the ancient and modern period provided evidence for the postulate that the medieval plague of leprosy was eliminated by an increased level of tuberculosis in Europe as the area urbanized.


'/>"/>

Contact: Rebecca Zeffert
rebeccaz@savion.huji.ac.il
972-548-820-661
The Hebrew University of Jerusalem
Source:Eurekalert  

Related medicine news :

1. UNESCO Chair Hosts Jews, Christians, and Muslims in Jerusalem Bioethics Conferences
2. Event Honoring Bill Gates Raises Over $1.5 Million for Sustainable Agriculture Research at The Hebrew University of Jerusalem
3. Robert H. Smith Feeding the Future with $15 Million Gift to Hebrew University of Jerusalem
4. Do Jerusalems Arabs and Jews receive a different quality of medical care?
5. Hallmark Insights' Employer Survey Reveals Cost-Savings Benefits of Health & Wellness Programs
6. Research reveals further progress toward AIDS vaccine
7. Beneath the Short White Coat: A Medical Student Reveals All
8. Northwestern Mutual Survey Reveals That Most Americans Are Putting Their Income at Risk
9. BenefitPackages.com Reveals the Truth About No or Low Cost Medicare Supplement Plan Options Including Anthem Blue Cross Freedom Blue Regional PPO
10. AIDS research reveals a lack of family-planning programs in Uganda
11. Study Reveals Evidence of Heart Disease in Ancient Egyptian Mummies
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
DNA of Jesus-era shrouded man in Jerusalem reveals earliest case of leprosy
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Grove Investment Group (TGIG), has initiated cultivation and processing operations at its production ... and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
Breaking Medicine Technology: